Two expressed human genes sustain slightly more DNA damage after alkylating agent treatment than an inactive gene.
Alkylating agent damage was quantified in human T-lymphocytes by calculating gene-specific lesion frequencies and repair rates. At 3 time points after exposure to methyl methanesulfonate (0, 6, and 24 h), T-lymphocyte DNA was extracted, digested with HindIII, and divided into 2 aliquots. Apurinic sites were formed in the DNA fragments of both aliquots by heat-induced liberation of the N-methylpurines. The methoxyamine-treated aliquot provided gene fragments which were refractory to alkaline hydrolysis (full-length fragments), while the fragments in the untreated aliquot were cleaved at apurinic sites by hydroxide. After Southern blotting, lesion frequencies were calculated by comparing the band intensity of the full-length fragment to its unprotected counterpart. The restriction fragments analyzed were from the constitutively active dihydrofolate reductase (dhfr) plus hypoxanthine phosphoribosyltransferase (hprt) genes and from the transcriptionally inactive Duchenne muscular dystrophy gene (dmd). In decreasing order, the fragments containing the most lesions per kb of DNA were: hprt greater than dhfr greater than dmd. T-Lymphocytes from 2 females had 30% more heat-labile N-methylpurines in the active X-linked hprt gene than in the inactive X-linked dmd gene. The lesion frequency found in the male's lone hprt allele was the highest observed. These lesion frequency differences are discussed in terms of chromatin structure. After 6 and 24 h, no significant repair rate differences were observed among the 3 genes.
Bartlett
J D
JD
Department of Neurology and Genetics Laboratory, University of Vermont, Burlington 05401.
Scicchitano
D A
DA
Robison
S H
SH
D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D004249:DNA Damage; D004260:DNA Repair; D005260:Female; D015870:Gene Expression; D006801:Humans; D006898:Hydroxylamines / Q000494:pharmacology*; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics*; D007700:Kinetics; D008297:Male; D008741:Methyl Methanesulfonate / Q000494:pharmacology*; D009136:Muscular Dystrophies / Q000235:genetics*; D015183:Restriction Mapping; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics*; D013997:Time Factors; D014158:Transcription, Genetic
D006898:Hydroxylamines; D004247:DNA; C005214:methoxyamine; D008741:Methyl Methanesulfonate; D013762:Tetrahydrofolate Dehydrogenase; D007041:Hypoxanthine Phosphoribosyltransferase